SIGA Technologies (SIGA) Q2 2024 earnings summary

Executive summary

• Q2 2024 product revenues reached $21–21.8M, with H1 2024 at $44.6–47.2M, driven by strong U.S. government and international TPOXX sales, including both oral and IV formulations.

• Net income for Q2 2024 was $1.8–2M, a turnaround from losses in 2023, reflecting improved sales and operational performance.

• A special cash dividend of $0.60 per share ($43M total) was paid in April 2024.

• Recent $112.5–113M BARDA contract option for oral TPOXX was exercised, with deliveries expected to begin within 90 days and a substantial portion delivered before year-end.

• TPOXX continues to be positioned as a critical antiviral for smallpox and mpox, with ongoing clinical trials and regulatory submissions in multiple regions.

Financial highlights

• Q2 2024 product revenue: $20.7–21.8M; H1 2024: $44.6–47.2M, up sharply from prior year.

• Q2 2024 pre-tax operating income: $1–2.9M; H1 2024: $12M, compared to losses in 2023.

• Net income for Q2 2024: $1.8–2M; H1 2024: $12M.

• Fully diluted EPS: $0.03 for Q2 2024; $0.17 for H1 2024.

• Cash and cash equivalents at June 30, 2024: $106.9–107M; no debt.

Outlook and guidance

• 2024 expected to be another year of strong product revenues, supported by new and existing contracts.

• Anticipates continued diversification of revenue base and growth in international markets.

• Confident in securing a new, larger, long-term U.S. government contract, potentially 5–10 years in duration.

• Supplemental NDA for mpox targeted for submission as early as 2025, pending positive trial data.

• Management expects liquidity and capital resources to be sufficient for at least the next twelve months.